Literature DB >> 30176117

Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.

Dirk Walter1, Philip Ferstl1, Oliver Waidmann1, Jörg Trojan1, Sylvia Hartmann2, Andreas A Schnitzbauer3, Stefan Zeuzem1, Klaus Kraywinkel4.   

Abstract

BACKGROUND & AIMS: Diverging trends of cholangiocarcinoma (CCA) incidence in different countries warrant further subtype-specific characterization. In this study, we aimed to determine current epidemiologic trends of CCA in Germany and evaluated impact of misclassification of perihilar CCA (pCCA) as intrahepatic CCA (iCCA).
METHODS: Subtype-specific incidence was assessed based on data of approximately 40 million German citizens from 2003 to 2014, and mortality data of entire Germany were assessed from 1998 to 2015.
RESULTS: Reclassification of pCCA to extrahepatic CCA (eCCA) led to an enhancement of an increasing average annual percentage change (AAPC) for iCCA in men (3.8 to 4.8) and women (3.3 to 4.8). Likewise, a stable or slightly decreasing trend in extrahepatic CCA was strengthened in women (AAPC: -0.2 to -0.9) and men (1 to 0.5). pCCA accounted for 13% of biliary tract tumours (iCCA: 46%, distal CCA: 41%). In line with incidence trends, mortality of iCCA in Germany increased for women (AAPC 7.8) and men (6.5), while it was stable for eCCA (women: -0.6, men: 2.1).
CONCLUSION: Incidence of iCCA in Germany is increasing while it is stable for eCCA. Misclassification of pCCA as iCCA is present, but clearly declining.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cholangiocarcinoma; incidence; misclassification; mortality

Mesh:

Year:  2018        PMID: 30176117     DOI: 10.1111/liv.13954

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

Review 1.  [Local and locoregional treatment of intrahepatic cholangiocarcinoma].

Authors:  Frank Wacker; Cornelia Dewald
Journal:  Radiologe       Date:  2022-01-03       Impact factor: 0.635

2.  Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012.

Authors:  Andrea A Florio; Jacques Ferlay; Ariana Znaor; David Ruggieri; Christian S Alvarez; Mathieu Laversanne; Freddie Bray; Katherine A McGlynn; Jessica L Petrick
Journal:  Cancer       Date:  2020-03-04       Impact factor: 6.921

3.  First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis.

Authors:  Christian Möhring; Jan Feder; Raphael U Mohr; Farsaneh Sadeghlar; Alexandra Bartels; Robert Mahn; Taotao Zhou; Milka Marinova; Georg Feldmann; Peter Brossart; Martin von Websky; Hanno Matthaei; Steffen Manekeller; Tim Glowka; Jörg C Kalff; Tobias J Weismüller; Christian P Strassburg; Maria A Gonzalez-Carmona
Journal:  Front Oncol       Date:  2021-11-10       Impact factor: 6.244

4.  Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy.

Authors:  Maximilian N Kinzler; Christina Klasen; Falko Schulze; Eva Herrmann; Andreas A Schnitzbauer; Jörg Trojan; Stefan Zeuzem; Peter J Wild; Dirk Walter
Journal:  J Clin Med       Date:  2022-04-06       Impact factor: 4.241

5.  Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019.

Authors:  Mee Joo Kang; E Hwa Yun; Kyu-Won Jung; Sang-Jae Park
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-07-29

Review 6.  In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease?

Authors:  Raphael Mohr; Burcin Özdirik; Jana Knorr; Alexander Wree; Münevver Demir; Frank Tacke; Christoph Roderburg
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

7.  Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.

Authors:  Maria A Gonzalez-Carmona; Christian Möhring; Robert Mahn; Taotao Zhou; Alexandra Bartels; Farsaneh Sadeghlar; Maximilian Bolch; Annabelle Vogt; Dominik J Kaczmarek; Dominik J Heling; Leona Dold; Jacob Nattermann; Vittorio Branchi; Hanno Matthaei; Steffen Manekeller; Jörg C Kalff; Christian P Strassburg; Raphael U Mohr; Tobias J Weismüller
Journal:  Sci Rep       Date:  2022-01-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.